Furthermore, the PI3K/Akt/mTOR signaling pathway is also aberrantly activated in a large number of AML patients, mostly due to alterations in growth factors and mutations in FLT3 itself, c-kit and Ras [69]. This evidence concerns the gene AKT1 and acute myeloid leukemia.